Zai Lab, Amgen announces trial agreement to evaluate zocilurtatug pelitecan

Zai Lab (ZLAB) announced a global clinical trial collaboration with Amgen (AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3-targeting antibody-drug conjugate, zocilurtatug pelitecan, in combination with Amgen’s Imdelltra, a DLL3-targeting Bispecific T-cell Engager, BiTE, therapy in patients with extensive-stage small cell lung cancer, ES-SCLC. As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the safety and efficacy of zoci in combination with Imdelltra in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply Amgen with the study drug.